FDA Oncology Announcements

JAK inhibitor × Myeloid × Clear all

3 Announcements

FDA approves fedratinib for myelofibrosis

Trial: JAKARTA
Drug: INREBIC (fedratinib) · JAK inhibitor
Condition: Myeloid

FDA Approves Ruxolitinib

Drug: Jakafi (ruxolitinib) · JAK inhibitor
Condition: Myeloid

Ruxolitinib

Drug: Jakafi oral tablets (ruxolitinib) · JAK inhibitor
Condition: Myeloid